Natalia Udvorkova

Bratislava, BL, Slovakia

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 8 publications

Therapeutic targeting of folate receptor alpha (FRα) by antibody-polymer-drug conjugate in testicular germ cell tumors.

Therapeutic targeting of folate receptor alpha (FRα) by antibody-polymer-drug conjugate in testicular germ cell tumors.

Journal: Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie

Published: May 12, 2026

Correction: Low level of plasma DNase is associated with worse clinical outcome in testicular germ cell tumor patients and exogeneous DNase I improves cisplatin treatment efficacy.

Correction: Low level of plasma DNase is associated with worse clinical outcome in testicular germ cell tumor patients and exogeneous DNase I improves cisplatin treatment efficacy.

Journal: PloS one

Published: December 31, 2025

Therapeutic efficacy of sacituzumab govitecan in recurrent refractory germ cell tumors.

Therapeutic efficacy of sacituzumab govitecan in recurrent refractory germ cell tumors.

Journal: Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie

Published: August 26, 2025

Low level of plasma DNase is associated with worse clinical outcome in testicular germ cell tumor patients and exogeneous DNase I improves (Leverages) cisplatin treatment efficacy.

Low level of plasma DNase is associated with worse clinical outcome in testicular germ cell tumor patients and exogeneous DNase I improves (Leverages) cisplatin treatment efficacy.

Journal: PloS one

Published: June 11, 2025

Low level of plasma DNase is associated with worse clinical outcome in testicular germ cell tumor patients and exogeneous DNase I improves cisplatin treatment efficacy.

Low level of plasma DNase is associated with worse clinical outcome in testicular germ cell tumor patients and exogeneous DNase I improves cisplatin treatment efficacy.

Journal: PloS one

Published: June 11, 2025

Mirvetuximab Soravtansine Induces Potent Cytotoxicity and Bystander Effect in Cisplatin-Resistant Germ Cell Tumor Cells.

Mirvetuximab Soravtansine Induces Potent Cytotoxicity and Bystander Effect in Cisplatin-Resistant Germ Cell Tumor Cells.

Journal: Cells

Published: November 28, 2024

Antibody-drug conjugates as a novel therapeutic modality to treat recurrent refractory germ cell tumors.

Antibody-drug conjugates as a novel therapeutic modality to treat recurrent refractory germ cell tumors.

Journal: American journal of physiology. Cell physiology

Published: June 24, 2024

Effect of the PARP inhibitor veliparib on germ cell tumor cell lines.

Effect of the PARP inhibitor veliparib on germ cell tumor cell lines.

Journal: Oncology letters

Published: April 28, 2022

Showing 1-8 of 8

Last Updated: 09/26/2026